News Merck, Pfizer and Gilead all interested in Medivation buy-ou... Sanofi has competition in its bid to acquire cancer specialist
News Zepatier to add competition to Europe’s hep C market Will company pursue same aggressive pricing strategy in Europe?
Views & Analysis Many millions still untreated – but hep C boom is already ov... Gilead has led a revolution in curing hepatitis C, but now faces a slowdown.
News German pricing changes to hit blockbuster revenues But pharma will be able to negotiate confidential prices.
News Lily gets FDA nod for SERD-CDK 4/6 combo in breast cancer Eli Lilly's imlunestrant (Inluriyo) for breast cancer has received a new FDA approval, in combination with CDK4/6 inhibitor abemaciclib (Verzenio).
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
